Tradestie Institutional Equity Comparison Engine

CLYM vs QNRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while QNRX counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus QNRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against QNRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner QNRX
CLYM N/M vs QNRX N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CLYM
1Y +399.5% vs -82.0% ยท 52W Pos 45% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
1M Return -12.81%
1Y Return +399.46%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0
QNRX NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.28
-2.35% 1D
Market Cap $16.1M
1M Return -18.2%
1Y Return -81.96%
Forward P/E N/M
Unified AI Score
46.1 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +399.46% QNRX -81.96% Spread: +481.42 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% QNRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs QNRX. Trailing 12-month operating profitability (CLYM 0.0% vs QNRX 0.0%) and valuation multiples (CLYM N/M vs QNRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (3) vs QNRX (3)
Institutional Metric CLYM QNRX Criterion Row Winner
Market Capitalization Scale $545.1M $16.1M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 7.6x Lower Multiple QNRX
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -142.6% Higher ROE CLYM
52-Week Range Position Momentum 45% ($2โ€“$18) 0% ($3โ€“$24) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 106% Vol 1.34ฮฒ ยท 74% Vol Lower Realized Risk QNRX
Unified Institutional Score Composite Signal 43.7 / 100 (HOLD) 46.1 / 100 (HOLD) Higher Composite QNRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs QNRX Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
QNRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QNRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor QNRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.